Background: The addition of HER2-targeted agents to standard treatment has been shown to improve outcomes for HER2 positive metastatic breast cancer patients. We undertook a meta-analysis to evaluate the efficacy of HER2-targeted therapy in addition to standard treatment in metastatic breast cancer patients.
The mainstay of metastatic breast cancer treatment is cytotoxic chemotherapy and hormone therapy [1] . Patients with HER2 positive disease are less responsive to these standard treatments and have previously experienced poorer outcomes than individuals with HER2 negative cancer [2] [3] [4] [5] . For this reason, the development of effective HER2-targeted therapies has been heralded as a significant milestone in breast cancer treatment [6] [7] [8] . In 2001, the trastuzumab (Herceptin) registration trial demonstrated its benefit in combination with chemotherapy by improving significantly overall response rates and survival compared with chemotherapy alone [7] . Due to these encouraging early findings, trastuzumab was rapidly adopted in developed countries and is now routine clinical care for HER2 metastatic breast cancer treatment.
Over the last decade, there has been a rapid increase in the number of clinical trials involving trastuzumab and the newer HER2 therapies. These trials have evaluated HER2 agents in combination with a range of therapeutic partners, including chemotherapy and hormone treatments [9, 10] . The emergence of resistance to first-line trastuzumab has prompted the assessment of HER2 therapies as second and subsequent lines of treatment. The volume of activity in this area is illustrated by the number of clinical trials listed on the USA National Library of Medicine registry [11] . We identified 84 phase II and 22 phase III trials across eight HER2-targeted therapies examining treatment efficacy in metastatic breast cancer. While trial activity has continued unabated, the assessment of HER2 status has remained the subject of continued debate. As a consequence, HER2 testing itself may confound the interpretation of clinical trial outcomes of HER2 therapies [12, 13] .
The unprecedented number of clinical trials of HER2 therapies for metastatic breast cancer presents an ideal opportunity to more precisely quantify the magnitude of the benefits delivered by these agents [14, 15] . In this study, we undertook a meta-analysis to evaluate the efficacy of the addition of HER2 agents over standard treatment alone. Specifically, we compared the outcomes of overall survival (OS), the intermediate endpoints of time to progression (TTP), progression-free survival (PFS) and overall response rate (ORR) as these are the main endpoints used in clinical trials to evaluate the efficacy of HER2 cancer treatments.
materials and methods

definition of HER2 therapy
Potential HER2-targeted agents were identified through clinical trial registries [11, [16] [17] [18] . We defined HER2-targeted therapy as treatment targeting the HER2 receptor exclusively (e.g. trastuzumab, lapatinib, pertuzumab and trastuzumab-MCC-DM1) or as a multi-targeted treatment with the HER2 receptor as one of its targets (e.g. neratinib). Treatments evaluating targets on the downstream signalling pathway such as mTOR and PARP inhibitors were not the focus of this study.
trial criteria
We included prospective phase II or III randomised controlled trials (RCTs) comparing the efficacy of a HER2-targeted therapy in addition to 'standard treatment' (chemotherapy and/or hormone therapy) in metastatic breast cancer. We included trials consisting of metastatic patients (stage 4) alone and those including patients with stage 4 and locally advanced disease (stage 3b or 3c). We also included trials of metastatic breast cancer patients with a pre-specified subset of HER2-positive patients.
We excluded trials if they compared only the efficacy of different HER2 therapy dosing schedules, evaluated HER2-targeted vaccines and reported only quality of life measures, toxic effects, pharmacokinetic outcomes or patterns of recurrence without efficacy outcomes.
search strategy
We identified trials by searching Medline, Embase, conference proceedings (American Society of Clinical Oncology, San Antonio Breast Conference, European Society for Medical Oncology), prospective clinical trial registers and scanning the reference lists of key trials and review articles.
The search period for published literature was 1996 (based on the first reported trial of trastuzumab efficacy in humans) to the end of December 2009. No language restrictions applied. Medline and Embase were searched using mapped terms 'trastuzumab', 'Herceptin' 'lapatinib', 'Tykerb', 'pertuzumab', 'neratinib' and the exploded MeSH term 'breast neoplasms' and search line [(breast or mammary) and (cancer* or tumour* or tumor* or neoplas* or metastas* or carcinoma)] [19] .
We searched conference proceedings via online websites at www.asco.org, www.esmo.org and www.sabcs.org, or hand searched older conference proceedings from 2001 (the date of the pivotal randomised controlled registration trial) [7] to 2009. We reviewed trial registries to ensure the completeness of included trials [11, [16] [17] [18] .
Two reviewers (CH and AD) assessed independently the titles and abstracts of retrieved articles to determine trial inclusion. Any disagreements between reviewers were resolved by a third researcher (SP). The full-text manuscripts of trials likely to meet the inclusion criteria were subsequently reviewed.
data extraction
We based our data abstraction on Cochrane guidelines [20] . Two independent reviewers (CH and SP) extracted trial data including trial design, patient eligibility, baseline patient characteristics, dosing regimens, line of treatment, method of HER2 identification, duration of follow up and treatment changes on disease progression. Discrepancies in data extraction were resolved by discussion. Data were extracted by trial not publication. If the trial results were reported in multiple publications, we extracted the most recently reported endpoints.
Our main endpoints of interest were OS and the corresponding intermediate endpoints TTP, PFS and ORR as these are the main endpoints used in HER2 clinical trials. We extracted hazard ratios (HRs) and 95% confidence intervals (CIs) for the outcomes OS, TTP and PFS. For the outcomes of overall response rate (ORR), complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), clinical benefit rates (CBR), time to treatment failure (TTF) and number of deaths, we either extracted or derived the number of patients with the outcome of interest (numerator) and the total number of patients in the treatment arm (denominator). OS was defined as time of randomisation to time of death from any cause, PFS was defined as the time from randomisation until objective tumour progression or death and TTP was defined as the time from randomisation until objective tumour progression (TTP did not include deaths) [21] . We extracted outcome measures based on the intention-to-treat analysis (ITT). Where possible we also used results reported from independent committees. Where outcome measures were not reported, we contacted the investigators to provide the data. We received correspondence and added additional data for PFS for the trial of In choosing denominators to use in our meta-analysis, our preference was the ITT group, the total number of patients randomised in the trial. If this data were not available, we then chose to use the assessable patients in each arm, i.e. the number of patients receiving treatment. For response rates, our preference was to include all randomised patients (ITT analysis). If this was not possible, we included all patients receiving treatment (assessable patients) and lastly only the evaluable patients (those who had had a response).
quality assessment
We modified established guidelines [20] to assess the methodological quality of included trials according to the criteria outlined in Table 1 .
statistical analyses
Log HRs and standard errors were calculated for time to event data [22] . Individual trial log HRs were pooled using the inverse-variance method, with rate-based secondary outcomes pooled using the Mantel-Haenszel method [20, 22, 23] . Heterogeneity of trial results was assessed with the I 2 statistic, with I 2 of <25% indicating low heterogeneity [20] . Outcomes with low heterogeneity were analysed using fixed effects models; otherwise random effects models were used. In line with clinical practice, a sensitivity analysis was carried out after anthracyclines were removed from the analysis (1 trial) [7] . All analyses were conducted using the 'metan' procedure in Stata Version 10 for Windows.
results study population
We reviewed the titles and abstracts of 1637 citations and 141 additional records derived from conference proceedings and review articles. The full-text versions of 103 papers were obtained to further determine eligibility. Nine manuscripts, representing eight trials were included in the meta-analysis [7, 9, 10, [24] [25] [26] [27] [28] [29] . The eight trials represented 1848 patients, 931 receiving the HER2 agent and 917 receiving standard treatment alone ( Figure 1 ). HER2-targeted agents were trastuzumab [7, 9, 10, 26, 27 ] (5 trials /1144 patients) and lapatinib [24, 25, 28] (3 trials /704 patients). Two trials included both HER2 positive and negative patients (only HER2 patients were included in our analysis) [25, 28] . Therapeutic partners included taxanes [7, 10, 25, 26 ] (4 trials), capecitabine [24, 27] (2 trials), anthracyclines [7] (1 trial) and hormone treatments [9, 28] (2 trials). All study participants were female and had measurable disease defined by either World Health Organisation or RECIST criteria, which was either described as visceral disease (4 trials) [24] [25] [26] 28] , by individual site (3 trials) [9, 10, 27] or number of metastatic sites (1 trial) [7] . Patients with brain metastases were usually excluded except in two studies if they were stable or treated [7, 24] or were not the only site of disease [26] . Four trials included patients with locally advanced disease (stage 3b or 3c) [24, 25, 27, 28] .
Three trials used a fixed number of chemotherapy cycles and in all trials patients were continued on the HER2 treatment until disease progression. Treatment was either first line (6 trials) [7, 9, 10, 25, 26, 28] or a second or subsequent line of treatment (2 trials) [24, 27] . The testing of HER2 positive disease was via immunohistochemistry (IHC) 2+ or 3+ in the early trials, [7, 10, 26] but this changed to incorporate only IHC3+ and in situ hybridisation (ISH) testing over time [9, 10, 24, 25, 27, 28] . Upon progression, most patients could cross-over from standard treatment alone to HER2 therapy [7, 9, 10, 24, 26] (5 trials); however in all but one trial [27] , it was not stated whether patients were allowed to continue on HER2-targeted therapy upon disease progression. The number and characteristics of participants in different subpopulations was reported inconsistently across trials. Therefore, further analysis of these groups was not carried out (Table 2) .
quality assessment
Overall study quality was variable. Five trials [9, 10, 24, 26, 27] reported an adequate sequence generation. Allocation concealment was either unclear or inadequate in all trials. Five trials [9, 10, 24, 26, 27] were open label and only two [25, 28] were adequate in terms of reporting blinding. We found consistent reporting of outcome data, with six of the eight trials using the ITT analysis of survival outcomes [7, 9, 10, 24, 25, 28] and all eight trials reported all results for endpoints of interest. Only two trials provided information on prospective centralisation of HER2 testing [7, 9] and only four were rated adequate in terms of independent blinding to progression [7, 9, 24, 25] (Table 3) .
outcomes
Our meta-analysis demonstrated a 22% reduction in the hazard of death with the addition of HER2-targeted therapies to standard treatment (5 trials, 1329 patients, HR 0.78; 95% CI 0.67-0.91) (Figure 2 ). The benefit of HER2-targeted agents over standard therapy was also seen with the intermediate endpoints of TTP (HR 0.56; 95% CI 0.48-0.64) and PFS (HR 0.63; 95% CI 0.53-0.74) but to a greater extent than OS (Figures 3 and 4 , Table 4 ).
The addition of HER2-targeted therapy to standard treatment increased ORR by 67% [relative risk (RR) 1.67; 95% CI 1.46-1.90] ( Figure 5 ). The addition of HER2 agents was also favourable for the outcomes of complete response (RR 2.00; 95% CI 1.24-3.21) and partial response (RR 1.61; 95% CI 1.38-1.87). Patients were more likely to have progressive disease or stable disease if they were treated with standard therapy alone (Table 4) .
Our sensitivity analysis, excluding data from the trial arms with anthracyclines, demonstrated similar results for all outcomes (Table 4) . This meta-analysis has shown that the addition of HER2-targeted therapies to standard treatment delivers a 22% improvement in OS. Intermediate endpoints show a 37% and 44% improvement for PFS and TTP, respectively, and an increase in ORR of 67%. Although these figures are very similar to those reported in the pivotal registration study, [7] it is important to note that the CIs for many of the individual trials conducted over the last decade crossed unity. The pooled results generated in the current study thus alleviate some of the residual uncertainties regarding the benefit of HER2 therapies. Five of the eight trials [7, 9, 10, 24, 26] included in our metaanalysis allowed cross-over from standard treatment to HER2 therapy at the point of progression or following toxicity to chemotherapy. Cross-over may account for the lesser impact of HER2 therapies on survival compared with their effect on the intermediate endpoints (TTP, PFS) and response rates [35, 36] . Attenuation of the OS effect implies that patients receiving HER2 therapies after progressing on standard therapy may not necessarily be disadvantaged compared with those receiving first-line combination therapy.
Our meta-analysis provides an opportunity to comment on current clinical practice as it relates to the evidence base regarding HER2 therapies. Despite the large volume of literature on HER2 therapies, only eight RCTs were identified in this analysis. Most of the literature (74% of the 103 full-text articles we reviewed) comprised observational, nonrandomised open label or single-arm trials. These trials often included only small numbers of patients and did not report on any survival outcomes (OS, TTP or PFS).
Based on the observational trials excluded from our review and audits of prescribing practice [37, 38] , it appears that physicians have assumed that the additional clinical benefit conferred by trastuzumab is the same regardless of its chemotherapeutic or hormonal partner. Yet this meta-analysis shows that only a very small number of HER2 combination therapies have actually been evaluated in an RCT design, specifically anthracyclines, taxanes, capecitabine and aromatase inhibitors (letrozole and anastrozole). Interestingly, two trials in our meta-analysis demonstrate the efficacy of the capecitabine/HER2 combination despite the early in vitro data which suggested that it would not be a successful treatment option [39, 40] . Of note, none of the RCTs published to date included vinorelbine, although it has demonstrated efficacy in nonrandomised or single-arm trials and an RCT when compared with taxanes [32, 41] . A similar problem is noted with gemcitabine which has not been assessed in RCTs in the metastatic setting, yet is also prescribed widely [42, 43] . We found one RCT comparing carboplatin triplet combinations, but this was excluded from our analysis as trastuzumab was included in both trial arms [33] . While it may be beneficial to undertake further clinical trials comparing the efficacy of HER2 therapy over chemotherapy, this is likely to be undesirable from a patient perspective now that HER2 agents are standard of care for HER2 positive metastatic breast cancer.
The use of HER2 agents in combination with drugs which have not been tested in RCTs may be in part driven by changes in adjuvant breast cancer management. Nowadays anthracyclines are used less frequently and most adjuvant regimens for HER2 positive patients include trastuzumab and taxanes either alone or as part of triplet therapy. It remains unknown whether individuals who have been exposed to these agents in the adjuvant setting will respond to these treatments to the same extent, if at all in the metastatic setting. Given the different therapeutic partners and small number of trials, we were unable to address this issue by undertaking a subgroup analysis of individual therapeutic partners. These limitations together with constant changes in clinical practice argue for an ongoing commitment to building an unbiased and contemporary evidence base to support the best use of HER2 therapies.
This study has a number of limitations, some of which are inherent in meta-analytic approaches and others specific to our review. We did not have individual patient data so as to verify independently and update outcomes data presented in publications. Further we were unable to verify randomisation [44] . Reporting varied greatly across included trials in terms of the endpoints used and the way in which they were expressed. HRs and CIs for the endpoints included in our analysis were not always reported in individual trials; instead trials reported the duration of benefit in months, weeks or days. We attempted to address some of the gaps by contacting individual investigators, but in all but two cases the authors failed to provide additional data. Importantly, there was a high degree of variability in the treatment regimens deployed and the method used to determine HER2 positivity, both of which are likely to impact on our findings.
In conclusion, this study provides clear evidence of the benefit of HER2-targeted agents over standard treatment alone in metastatic breast cancer, in terms of OS and its intermediate endpoints. Ongoing commitment to the development of welldesigned RCTs is required to determine the optimal therapeutic partners for HER2-targeted therapies and the sequence in which these agents are best administered. Outcome analysed using random effects models. HR, hazard ratio; RR, relative risk; CI, confidence interval; OS, overall survival; PFS, progression-free survival; TTP, time to progression; ORR, overall response rate; CBR, clinical benefit ratio; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; TTF, time to treatment failure.
